Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

65 Interestingly, one study (GINDON study) showed a trend in favor of EGb 761 ® plus donepezil vs either agent alone, with regard to clinically meaningful cognitive functioning and global improvement. 55 Comparative data also demonstrated an improved safety profile with EGb 761 ® vs AChEIs and memantine. 65 3.6 Expert consensus/conclusion statements Herein, we summarize the Expert Panel's agreed consensus statements regarding the use of EGb 761 ® in the management of AD, VaD, BPSD, and MCI, along with other specific statements on clinically relevant issues (Table 2 ).
A post hoc analysis of data from the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial in a subgroup of patients diagnosed with PAD showed a trend for a benefit of clopidogrel plus aspirin over aspirin alone in this population, with a reduction in MI rates. 19 , 34 At the time the REACH Registry was established, the novel oral antithrombotic agents prasugrel, ticagrelor, vorapaxar, or rivaroxaban were not available.
Whereas quantitative reverse transcriptase PCR (qRT-PCR) analysis in livers of mice fed a CD showed a trend of decreased gene expression related to fatty acid oxidation and secretion in Arid1a LKO mice (Supplementary Fig. 3a-c), the mRNAs encoded by these genes involved in FAO ( Pparα , Cpt1a , Acox1 , Pgc1α , Hmgcs2 , etc.) and secretion ( Mttp ) were significantly reduced in the Arid1a LKO mice with HFD administration.
2 , 3 Third, in none of our rodent experiments has NT3 treatment caused any detectable hypersensitivity, spasticity, or muscle weakness; rather, after bilateral CST injury in rats, intramuscular delivery of AAV‐preproNT3 reduced spasms, slightly improved grip strength, and showed a trend toward reducing mechanical hyperalgesia. 14 We used fMRI during electrical stimulation of the wrist to explore recovery of somatosensory responsiveness to adhesive patches attached to the wrist.
Although less than 30% of the AZA patients completed the planned 12 cycles, the study showed a trend toward improvement in RFS in the patients receiving more AZA cycles. 101 Maintenance with CC-486, a novel oral AZA formulation that allows extended dosing and prolonged activity, has also been explored, although with limited data on frequency of prior therapy with HMAs. 98 Thirty patients in CR after alloSCT received CC-486 once daily for 7 or 14 days in a 28-day cycle for up to 12 cycles and among these, 9 had received AZA prior to transplant.